Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Bristol Meyers Squibb Company

Viiv Healthcare UK Limited

David Bertil Frennesson

Mark George Saulnier

Kurt Zimmermann

David R Langley

Upender Velaparthi

Dolatrai M Vyas

Mark D Wittman

Neelakantan Balasubramanian

Peiying Liu

Xiaopeng Sang

Edward H Ruediger

Paul Michael Scola

Piyasena Hewawasam

Kap-Sun Yeung

Makonen Belema

Harold A Mastalerz

Katharine A Grant-Young

Alan Xiangdong Wang

Guifen Zhang

Walter Lewis Johnson

Zhaoxing Meng

Juliang Zhu

Mikael Mahler

Karen M Stoffan

B Narasimhulu Naidu

Michael G Yang

Li-Qiang Sun

Yong-Jin Wu

Guanglin Luo

Steven H Spergel

Carol Bachand

Jie Chen

Carolyn Diane Dzierba

Eric Mull

Kyle E Parcella

Zili Xiao

Anne Marinier

Junqing Guo

Amy C Hart

Jianliang Shi

Brian Lee Venables

Francis Beaulieu

Ningning Xu

Stephan Roy

James G Tarrant

Joel Francis Austin

Matthew Reiser Patton

Xirui Hu

Nicholas A Meanwell

John F Kadow

Tao Wang

Zhongxing Zhang

James Aaron Balog

John A Bender

Eric P Gillis

Omar D Lopez

Denis R St Laurent

Gan Wang

Van N Nguyen

Manoj Patel

Audris Huang

Kevin M Peese

Ashok Vinayak Purandare

Timothy P Connolly

Ramkumar Rajamani

Lalgudi S Harikrishnan

Yong Tu

Muthoni G Kamau

Michael S Bowsher

Hasibur Rahaman

Michael E Mertzman

Samayamunthula Venkata Satya Arun Kumar Gupta

Christiana Iwuagwu

Roshan Yadavrao Nimje

Neelakantan Balusubramanian

Byron Hepler Long

Michael C Mertzman

Joel F Austin

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Triazolopyridinyl compounds as kinase inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases. 

1,3-dihydroxy-phenyl derivatives useful as immunomodulators

Combinations comprising biphenyl derivatives for use in the treatment of HCV

Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds. 

Substituted azaindazole compounds

The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

Macrocycles and macrocycle stabilized peptides

Disclosed are azaindazole compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein W is CRor N; and R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds. 

Azaindazole compounds

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

Pyrrolotriazine kinase inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Growing community of inventors

Naugatuck, CT, United States of America

David Bertil Frennesson